Organic Process Research & Development 2010, 14, 1448–1452
Modified Chelation-Controlled Reduction of an N-Acryloyloxazolidin-2-one†
Terrence J. Connolly,*,‡ Zhixian Ding,‡ Yumin Gong,§ Michael F. MacEwan,‡ Jan Szeliga,§ and Asaf Alimardanov⊥
Wyeth Research, 401 North Middletown Road, Pearl RiVer, New York 10965, United States
Abstract:
of diastereomers, shown as 3 and dist-3 in Figure 1, with the
latter being favored by a ratio of 75:25 (entry 1, Table 1).
Addition of 1.2 equiv of magnesium bromide led to a reversed
sense of stereoinduction, and 3 was formed over dist-3 in a
ratio of 95:5.
A key step in the synthesis of an optically active aminoalcohol-
containing active pharmaceutical ingredient (API) involved the
diasteroselective reduction of a chiral 3-acryloyl-4-benzyloxazoli-
din-2-one. Preliminary work identified that excellent facial selectiv-
ity could be achieved by performing the hydrogenation in
tetrahydrofuran in the presence of magnesium bromide. During
an intermediate scale-up to support a 500-g batch of API, a side
reaction between the product and magnesium bromide was
observed that led to a significant deterioration in the isolated yield
of product. An examination of alternative chelators and processing
solvents identified that magnesium chloride in 2-methyltetrahy-
drofuran offered comparable facial selectivity with significantly
diminished liabilities for scale-up. This revised process was
incorporated into campaigns to produce larger lots of API and
afforded the product in 85% yield, averaged over 18 batches.
These results were explained on the basis of the preferred
conformation of 2. In the absence of Lewis acid, compound 2
existed predominantly as the anti-2 conformer. Literature
precedent based on other oxazolidin-2-one derivatives supports
the major conformation as anti-2 based on dipole-dipole
interactions between the two carbonyl groups.6,7 Addition of
magnesium bromide appeared to change the preferred confor-
mation to the syn-2 form, and the major product from
hydrogenation became 3. Others have reported similar magne-
sium salt-mediated reversals in the facial selectivity of R,ꢀ-
unsaturated imides during conjugate additions and oxidations
and have invoked similar mechanistic explanations.8,9
The effects of reaction temperature and applied pressure of
hydrogen were evaluated briefly (entries 2-6, Table 1). This
limited data set indicated that the working pressure of hydrogen
could be reduced to 40 psig if the temperature was maintained
at 50 °C. At lower temperatures, conversion slowed signifi-
cantly, and the reduction was not complete after 4 h (entries
4-6, Table 1).10
Introduction
Recently, we disclosed details on the route selection and
early scale-up efforts that resulted in the successful synthesis
of 5 from 11 (Scheme 1). Conversion of 2 to 3 used a newly
discovered diastereoselective hydrogenation protocol, followed
by an enolization-azidation sequence at -40 °C2,3 based on
Evans methodology.4 The details surrounding the development
of conditions for conversion of 2 to 3 and the robust process
that resulted are the subjects of this communication.
To support the preparation of a 500-g batch of active
pharmaceutical ingredient (API) 5, the reduction was scaled up
15-fold and performed in a kilo-lab reactor at 50 °C and 55
psig hydrogen. Laboratory experiments had shown that the
solubility of magnesium bromide was sufficient enough in a
mixture of IPA and water that it would not interfere with the
isolation of 3. Therefore, following removal of the catalyst, the
solvent was exchanged to IPA and water added to effect
crystallization of the product. Although laboratory yields had
been 80%, the first scale-up to the kilolab resulted in 33% yield.
An impurity was found in the filtrate that had m/z of 369, and
a stress test done after the kilolab run showed that 3 reacted
with MgBr2 at elevated temperature in a mixture of THF and
IPA to generate a peak with m/z 369, presumably formed via
Results and Discussion
As reported previously, direct hydrogenation of 2 over dry
palladium on carbon5 at 450 psig hydrogen produced a mixture
† Wyeth was acquired by Pfizer on October 15, 2009.
* Address correspondence to this author at the above mailing address, attention
B222/2125. E-mail: terrence.connolly@pfizer.com.
‡ Chemical Development.
§ Analytical and Quality Science.
⊥ Discovery Synthetic Chemistry.
(1) Alimardanov, A.; Nikitenko, A.; Connolly, T. J.; Feigelson, G.; Chan,
A. W.; Ding, Z.; Ghosh, M.; Shi, X.; Ren, J.; Hansen, E.; Farr, R.;
MacEwan, M.; Tadayon, S.; Springer, D.; Kreft, A. F.; Potoski, J. R.
Org. Process Res. DeV. 2009, 13, 1161–1168.
6
11,12 (Figure 2). Preparative LC was eventually used to obtain
(2) Safety screening performed in-house generated results in line with
those reported previously by Merck workers for triisopropylbenzene
sulfonyl azide. See: Tuma, L. D. Thermochim. Acta 1994, 243, 161–
167.
(6) Prashad, M.; Liu, Y.; Kim, H.-Y.; Repic, O.; Blacklock, T. J.
Tetrahedron: Asymmetry 1999, 10, 3479–3482.
(7) Davies has published single-crystal data for valine-derived products
related to 3 that also support the anti-relationship between the carbonyl
groups of the oxazolidinone and N-acyl groups. See: Bull, S. D.;
Davies, S. G.; Garner, A. C.; Kruchinin, D.; Key, M.-S.; Roberts,
P. M.; Savory, E. D.; Smith, A. D.; Thomson, J. E. Org. Biomol. Chem.
2006, 294, 5–2964.
(3) Details on the work that enabled the conversion of 3 to 4 to be
performed at -40 to -50 °C have been communicated recently. See:
Connolly, T. J.; Hansen, E. C.; MacEwan, M. F. Org. Process Res.
DeV. 2010, 14, 466–469.
(4) Evans, D. A.; Britton, T. C.; Ellman, J. A.; Dorow, R. L. J. Am. Chem.
Soc. 1990, 112, 4011–4030.
(8) Adam, W.; Zhang, A. Eur. J. Org. Chem. 2004, 147, 152.
(9) Kanai, M.; Muraoka, A.; Tanaka, T.; Sawada, M.; Ikota, N.; Tomioka,
K. Tetrahedron Lett. 1995, 36, 9349–9352.
(5) The process does require that dry catalyst be used since water has a
significant detrimental impact on the process. Palladium on alumina
can be used in cases where handling pyrophoric, dry palladium on
carbon is not acceptable.
(10) This screening was performed using an Endeavor Catalyst Screening
System from Biotage/Argonaut. Longer reaction times at lower
temperatures were not evaluated.
1448
•
Vol. 14, No. 6, 2010 / Organic Process Research & Development
10.1021/op100074m 2010 American Chemical Society
Published on Web 10/21/2010